Evidence map›Paper›PMID 39855565›Full record

ArticleTransplantation and cellular therapy2025

Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

Blachy J Dávila Saldaña, Kirk R Schultz, Archana Ramgopal, Julie R Boiko, Kristen Beebe, Paul A Carpenter, Sherwin S Chan, Sophie Paczesny, Paibel Aguayo-Hiraldo, Geoffrey D E Cuvelier and 3 more

Abstract read
In one paragraph

Article in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Blachy J Dávila SaldañaDivision of Blood and Marrow Transplantation, Children's National Hospital, Washington, District of Columbia. Electronic address: blachy.davilasaldana@cchmc.org.
Kirk R SchultzBC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Archana RamgopalDepartment of Pediatric Bone Marrow Transplantation & Cellular Therapy, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Julie R BoikoTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, Washington.
Kristen BeebeBlood and Marrow Transplantation, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, Arizona.
Paul A CarpenterClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Sherwin S ChanDepartment of Radiology, Children's Mercy Kansas City, Kansas City, Missouri.
Sophie PaczesnyDepartment of Microbiology and Immunology and Pediatrics, Medical University of South Carolina, Charleston, South Carolina.
Paibel Aguayo-HiraldoCancer and Blood Disorders Institute, Children's Hospital Los Angeles, University Southern California Keck School of Medicine, Los Angeles, California.
Geoffrey D E CuvelierDepartment of Pediatric Oncology and Transplantation, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
Seth J RotzDivision of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, Ohio.
Christine N DuncanDepartment of Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kirsten M WilliamsAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.

Funding

Research and Education towards Solutions for Late effects to Innovate, Excel, and Nurture after chronic Graft-versus-Host Disease (RESILIENT after cGVHD)R13HL172559 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ROTZ, SETH J · 2024 to 2024
$37k
NHLBI NIH HHS R13 HL172559
6 · The paper itself

Abstract

While highly morbid forms of chronic graft versus host disease (cGVHD) and severe late effects of allogeneic hematopoietic cell transplantation (HCT) can impact children and adults alike, unique considerations arise in pediatric cases regarding diagnosis, monitoring, treatment, and likelihood of resolution. As children can present with atypical features of cGVHD and with more significant disease due to inability to communicate symptoms, they may be at increased risk for highly morbid forms of cGVHD and incur greater subsequent late effects, which may be more pronounced in those with underlying chromosomal breakage syndromes, with higher prevalence in pediatric HCT recipients. The long-term effects of cGVHD and its therapies include impaired immune reconstitution, leading to increased risks of infection and secondary malignant neoplasms. However, children also have the greatest potential for full immune reconstitution, due to thymus recovery that could impact the timing of vaccination with respect to tolerance and restoration of optimal immunity. Developing strategies to mitigate the late effects incurred with, and as a result of, cGVHD is of critical importance. The working group recommends surveillance strategies for late effects in patients with cGVHD, increased utilization of emerging diagnostic tools, integration of monitoring for cGVHD treatment response, and development of new treatments and specifies aims of future research endeavors.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationImmune ReconstitutionChildChronic DiseaseHumansChronic graft-versus-host diseaseImmune reconstitutionLate effectsPediatricSecondary malignanciesStem cell transplantation

Identifiers

PMID39855565
PMCPMC12146074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.